faculty portrait if available
Georgios Matthaiolampakis
Associate Professor
School Basic Pharm & Toxicol Sci
PHAR
318-342-7930
ULM logo

Georgios Matthaiolampakis, PhD
Associate Professor, School of Basic Pharmaceutical & Toxicological Sciences
Associate Director

Education

Ph D

2009, Pharmaceutical technology, drug delivery and nanotechnology,
Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras

BS

2005, Chemical Engineering
School of Chemical Engineering, National Technical University of Athens

Biographical Sketch

Professional Experience

  • 2017-Present: Adjunct Faculty 
    Biomedical Engineering, LA Tech, Ruston. 

  • 2016-Present: Assistant Professor Pharmaceutics (tenure-track)
    Department of Basic Pharmaceutical Sciences
    School of Pharmacy, University of Louisiana at Monroe

  • 2014-2016: Post-Doctoral Associate
    NCI Center of Cancer Nanotechnology Excellence, Department of Pharmaceutical Sciences
    School of Pharmacy, Northeastern University

  • 2010-2014: Research Scientist/Post-Doctoral Associate
    Division of Cancer Prevention with Dr. Basil Rigas, MD, MSc
    Department of Medicine, Stony Brook University, SUNY

​

Education

  • 2005-2009: Doctor of Philosophy, Pharmaceutical technology, drug delivery and nanotechnology, Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras

  • 2000-2005: Bachelor of Science in Chemical Engineering, School of Chemical Engineering, National Technical University of Athens

Research Interests

ABOUT US

We are interested in using polymer-based nanomedicine to promote scientific knowledge in cancer treatment. Preclinical protocols spanning from test-tube evaluation to animal models will provide the proof of principal for any future  approaches.

​

Our lab integrates nanotechnology, imaging science, gene therapy and cancer biology. Based on pharmaceutical sciences, we provide solutions on drug delivery using modern or more traditional approaches, in order to improve pharmacokinetic, biodistribution and absorption, water solubility and efficacy for smaller and bigger molecules. We expand to mechanistic studies of compounds and nucleic acids, for gene regulation and treatment on a panel of diseases.

​

With thousands of compounds in the preclinical pipeline, most of them limited by high lipophilicity, rapid elimination/metabolism, low absorption or unfavorable biodistribution profiles, we apply drug delivery methodology using dosage formulation techniques and nanotechology. While targeted delivery is steadily being recognized as a key ingredient for successfully delivering molecules to the desired tissue and cell, the possible applications have exponentially increased. 

 

 

Our overarching goals are: 

- To generate approaches that combine gene therapy with traditional chemotherapy to overcome chemoresistance and inhibit metastasis. 

- To develop effective and safe agents for the treatment of prevalent human cancers such as pancreatic, colon, skin, breast, and lung cancer

- To improve drug targeting utilizing single or dual targeted nanomedicines, by recognizing the dynamic tumor microenvironment and cancer biology.

-To promote student oriented research to help young scientists transition from the undergraduate to graduate level and beyond with knowledge in analytical methodology, gene therapy and cancer treatment approaches. 

 

 

 

 

Our immediate research projects involve:

1) The use of siRNAs or miRNAs to regulate gene expression of key ani-apoptotic genes to inhibit chemoresistance and metastasis in lung and pancreatic cancer.

2) Utilization of nanotechnology for targeted delivery

3) Formulation design for crossing the Blood Brain Barrier and treatment of glioblastoma multiform for delivery of therapeutic compounds

 

www.matthaiolampakislab.com/

 

Undergraduate and graduate students are always encouraged to contact us for training opportunities in our lab. PhD applicants with backgrounds in pharmacy, biology, chemistry, and chemical engineering, are encouraged to reach out for position openings.

Recent Publications

Hossian, A., Jois, S., Jonnalagadda, S., Mattheolabakis, G. (2020). Nucleic acid delivery with α-tocopherol-Polyethyleneimine-Polyethylene glycol nanocarrier system. International Journal of Nanomedicine.
Shrestha, L., Singh, S., Parajuli, P., Dahal, A., Mattheolabakis, G., Meyer, S., Jois, S. (2020). In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. Journal of Cancer.
Caceres, J., Munoz-Sagastibelza, M., Hossian, A., Paredes, J., Barrera, K., Mattheolabakis, G., Martello, A., Vignesh, S. (2019). Evaluation of the feasibility of intrapancreatic delivery of drug-loaded microparticles via endoscopic ultrasound fine-needle injection using a swine model. Endoscopy International Open.
Hossian, A., Sajib, M., Tullar, P., Mikelis, C., Briski, K., Mattheolabakis, G. (2019). Analysis of combinatorial miR treatments to regulate Cell Cycle and Angiogenesis. JoVE.
Hossian, A., Sajib, M., Tullar, P., Mikelis, C., Mattheolabakis, G. (2018). Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro. Scientific Reports.
Guorgui, J., Wang, R., Mattheolabakis, G., Mackenzie, G. G. (2018). Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice. Archives of Biochemistry and Biophysics.
Mattheolabakis, G., Milane, L., Singh, A., Amiji, M. (2015). Hyaluronic Acid Targeting of CD44 for Cancer Therapy: From Receptor Biology to Nanomedicine. Journal of Drug Targeting.
Berman, M., Mattheolabakis, G., Suresh, M., Amiji, M. (2016). Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opinion on Drug Delivery.
Milane, L., Singh, A., Mattheolabakis, G., Suresh, M., Amiji, M. (2015). Exosome Mediated Communication within the tumor microenvironment. Journal of Controlled Release.
Wong, C., Cheng, K., Papayannis, I., Mattheolabakis, G., Liqun, H., Gang, X., Negtai, O., Rigas, B. (2015). Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: Implications for their clinical pharmacology. Pharmaceutical Reserach.
Bartels, L., Mattheolabakis, G., LaComb, J., Vaeth, B., Zhi, J., Rigas, B., Mackenzie, G. (2015). The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: An effect mediated by cyclin D1. Carcinogenesis.
Mattheolabakis, G., Papayannis, I., Yang, J., Vaeth, B., Wang, R., Ouyang, N., Rigas, B., Mackenzie, G. (2016). Phospho-aspirin (MDC-22) prevents pancreatic carcinogenesis in mice. Cancer prevention research (Philadelphia, Pa.).
Singh, S., Xu, J., Amiji, M. (2016). EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. Nanomedicine.
Salzano, G., Costa, D., Sarisozen, C., Luther, E., Mattheolabakis, G., Dhargalkar, P., Torchilin, V. (2016). Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue. Small.
Hotta, R., Cheng, L., Graham, H., Nagy, N., Belkind-Gerson, J., Mattheolabakis, G., Amiji, M., Goldstein, A. (2016). Delivery of enteric neural progenitors with 5-HT4 agonist-loaded nanoparticles and thermosensitive hydrogel enhances cell proliferation and differentiation following transplantation in vivo. Biomaterials.
Mattheolabakis, G., Ling, D., Ahmad, G., Amiji, M. (2016). ., Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung. Pharmaceutical Reserach.
Mattheolabakis, G., Wang, R., Rigas, B., Mackenzie, G. G. (2017). Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles. International Journal Of Oncology.

Research Grants

Matthaiolampakis, G., "Novel nanocarrier based on a-tocopherol derivative for nucleic acid delivery" (Funded), Sponsored By University of Louisiana at Monroe, The University of Louisiana at Monroe, $4500. (May 2020 - April 2021).
Matthaiolampakis, G. (Principal), "Tumor Associated macrophage polarization and Lung Cancer" (Funded), Sponsored By LBRN, The University of Louisiana at Monroe, $70500. (2019 - 2020).
, "Combinatorial treatment of miRNAs and novel platinate against lung cancer" (Funded), Sponsored By LBRN, External to The University of Louisiana at Monroe, $. (May 2017 - April 2019).
Matthaiolampakis, G. (Co-Principal), "Acquisition of semi-prep/analytical HPLC and Benchtop freeze-dryer unit for ULM Bienville core facility" (), Sponsored By LBRN, The University of Louisiana at Monroe, $50000. (2018 - 2019).

Courses Taught

PHAR 5076ADVANCED PHARMACEUTICS, 2 course(s)

PHRD 4008PHARMACEUTICS I, 5 course(s)

PHRD 4029PHARMACEUTICS II, 8 course(s)

PHRD 4049INTEGRATED LAB SEQUENCE II, 8 course(s)

PHRD 5064PROBLEMS, 13 course(s)